Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label, Controlled, Randomized Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-beta.

Next Previous
Search
Trial Profile

A Phase II, Open-Label, Controlled, Randomized Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-beta.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX 1307 (Primary) ; Cisplatin; Gemcitabine; Granulocyte-macrophage colony-stimulating factors; Poly ICLC; Resiquimod
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms N-ABLE

    • Most Recent Events

    • 28 Jul 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 06 May 2011 Planned number of patients changed from 60 to 30.
    • 06 May 2011 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top